The Clinical Pharmacology and Use of Paroxetine, a New Selective Serotonin Reuptake Inhibitor

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Major depression afflicts a significant percentage of the population, and optimum therapy is often limited by the poor tolerability and lethality in overdose of the tricyclic antidepressants. The selective serotonin reuptake inhibitors (SSRIs) fluoxetine, sertraline, and, more recently, paroxetine are viewed as welcome additions to existing therapy. The SSRIs are as effective as the tricyclic antidepressants, but are not associated with their adverse effect profile. Paroxetine in dosages of 20-50 mg/day is as effective as the older classic antidepressants, including amitriptyline, imipramine, and doxepin. It is effective in the elderly and in patients with recurrent, resistant, or severe depression.

Original languageEnglish (US)
Pages (from-to)127-138
Number of pages12
JournalPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume14
Issue number2
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The Clinical Pharmacology and Use of Paroxetine, a New Selective Serotonin Reuptake Inhibitor'. Together they form a unique fingerprint.

  • Cite this